| ADR Ontology |
| ADR Term |
Neuromuscular blockade |
| ADR ID |
BADD_A03057 |
| ADR Hierarchy |
|
| Description |
The intentional interruption of transmission at the NEUROMUSCULAR JUNCTION by external agents, usually neuromuscular blocking agents. It is distinguished from NERVE BLOCK in which nerve conduction (NEURAL CONDUCTION) is interrupted rather than neuromuscular transmission. Neuromuscular blockade is commonly used to produce MUSCLE RELAXATION as an adjunct to anesthesia during surgery and other medical procedures. It is also often used as an experimental manipulation in basic research. It is not strictly speaking anesthesia but is grouped here with anesthetic techniques. The failure of neuromuscular transmission as a result of pathological processes is not included here. [MeSH] |
| MedDRA Code |
10029315 |
| MeSH ID |
D019148; D019148; D019148
|
|
ADR Severity Grade (FAERS)
|
|
|
ADR Severity Grade (CTCAE)
|
Not Available
|
| Synonym |
| Block neuromuscular | Neuromuscular block | Neuromuscular blockade | Neuromuscular Blockade | Blockade, Neuromuscular | Neuromuscular Block | Block, Neuromuscular |
|
|
| ADR Related Proteins |
| Protein Name |
UniProt AC |
TTD Target ID |
| Not Available | Not Available | Not Available |
|
| Drugs Leading to the ADR |
|
|
